Table 4.

Differential effects of antagonists or potentiators between GluN2 subunit genotypes.

	Treatment	WT	GluN2A KO	GluN2D KO	Ref. No.
Dopamine release (in vivo brain dialysis)	PCP (3 mg/kg, s.c.)	↑↑	↑↑	→	[69]
Locomotor activity	PCP (3 mg/kg, s.c.)	↑↑	↑↑	→	[69]
Sensitization	Subchronic PCP (3 mg/kg, s.c.)	↑↑	→	→	[69]
Motor performance (rotarod test)	PCP (3 or 5 mg/kg, s.c.)	↓↓	n.d.	↓	[70]
	UBP141 (3 mM, 20 µl, i.c.)	↓↓	n.d.	→	[70]
	CIQ (20 mg/kg, i.p.)	→	n.d.	↓↓	[70]
c-fos expression	PCP (10 mg/kg, s.c.)	↑↑↑	n.d.	↑ or →	[70]
	UBP141 (3 mM, 20 µl, i.c.)	↑	n.d.	→	[70]
	CIQ (20 mg/kg, i.p.)	↑↑↑	n.d.	↑↑↑	[70]

n.d., not determined.